NasdaqGS:SDGRHealthcare Services
How the End of SGR-2921’s Development at Schrödinger (SDGR) Has Changed Its Investment Story
Earlier this month, Schrödinger, Inc. announced it has ended the clinical development program for SGR-2921, its CDC7 inhibitor, following two patient deaths linked to the drug in a Phase 1 trial for acute myeloid leukemia and high-risk myelodysplastic syndromes.
Although preclinical and early trial data suggested potential, Schrödinger determined further development would be too challenging due to emerging safety concerns.
We’ll examine how the discontinuation of SGR-2921 due to safety...